Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

McMaster University

$120,000.00

Evaluating the impact of universal pharmacare on contraceptive use and unintended pregnancies in Ontario youth and young adults

EF 2021-22

Résumé
Canada remains the only high-income country with a universal healthcare system that does not include prescription drug coverage. Financial barriers to contraception have been cited as one of the reasons young Canadian females chose to use less effective methods of contraception, placing them at increased risk of unintended pregnancy. Understanding how access to drug insurance for contraceptives affects Canadian females and ensure they are not placed at a disadvantage because of unintended pregnancy and subsequent physical and mental health outcomes. In January 2018, the Ontario government introduced universal pharmacare for all prescription drugs, including contraceptives, listed on Ontario's public drug formulary to all Ontario children and youth under the age of 25 without copayments, including individuals already covered via private drug plans (OHIP plus). In April 2019, OHIP plus was revised to cover those who did not otherwise have access to private drug insurance (OHIP minus). While OHIP minus continued to provide free drug coverage to Ontarians under the age of 25 without alternate forms of drug insurance, many Ontario youth reverted back to their previous private drug plan or, in many cases, their parent's private drug plan. Confidential access to prescription medication for these individuals may have been compromised and copayments were reintroduced. Our objective is to investigate whether OHIP plus/minus impacted long-acting reversible contraceptive use, abortion use and birth in Ontario females under 25 years. Using secondary data extracted from administrative databases, we will use two analytical designs to examine the impact of OHIP plus/minus, time-series event analyses and difference-in-differences approaches. Our project will generate policy-relevant evidence regarding the impact of free and confidential access to contraception for policymakers and advocates as Canada continues to evaluate how best to provide drug coverage for all citizens.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
462559
Name
Guindon Godefroy E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Health Policy & Systems Management Research
Projecttitle
Evaluating the impact of universal pharmacare on contraceptive use and unintended pregnancies in Ontario youth and young adults
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Contraception; Healthcare Use; Insurance; Prescription Drug; Unintended Pregnancy
Abstract
Canada remains the only high-income country with a universal healthcare system that does not include prescription drug coverage. Financial barriers to contraception have been cited as one of the reasons young Canadian females chose to use less effective methods of contraception, placing them at increased risk of unintended pregnancy. Understanding how access to drug insurance for contraceptives affects Canadian females and ensure they are not placed at a disadvantage because of unintended pregnancy and subsequent physical and mental health outcomes. In January 2018, the Ontario government introduced universal pharmacare for all prescription drugs, including contraceptives, listed on Ontario's public drug formulary to all Ontario children and youth under the age of 25 without copayments, including individuals already covered via private drug plans (OHIP plus). In April 2019, OHIP plus was revised to cover those who did not otherwise have access to private drug insurance (OHIP minus). While OHIP minus continued to provide free drug coverage to Ontarians under the age of 25 without alternate forms of drug insurance, many Ontario youth reverted back to their previous private drug plan or, in many cases, their parent's private drug plan. Confidential access to prescription medication for these individuals may have been compromised and copayments were reintroduced. Our objective is to investigate whether OHIP plus/minus impacted long-acting reversible contraceptive use, abortion use and birth in Ontario females under 25 years. Using secondary data extracted from administrative databases, we will use two analytical designs to examine the impact of OHIP plus/minus, time-series event analyses and difference-in-differences approaches. Our project will generate policy-relevant evidence regarding the impact of free and confidential access to contraception for policymakers and advocates as Canada continues to evaluate how best to provide drug coverage for all citizens.
Competitiondate
202203
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Guindon, Godefroy E; Black, Amanda; Darling, Elizabeth K
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~